MPLT Stock Forecast & Price Target

MapLight Therapeutics is supported by a high-conviction, mechanism-led thesis because its ML-007C-MA program targets the large unmet needs in schizophrenia and Alzheimer’s disease psychosis with a fixed-dose M1/M4 agonist plus peripheral anticholinergic designed to preserve central efficacy while limiting peripheral side effects. The company’s recent ZEPHYR Phase 2 readout showed a 4.5-point placebo-adjusted PANSS improvement and a 0.37 effect size, with meaningful cognitive benefit, low discontinuation, and no urinary retention, suggesting differentiated tolerability and dosing convenience versus Cobenfy. With a $150M PIPE financing, Fast Track designation in Dec 2025, and VISTA Phase 2 topline expected in 2H27, the market appears to underappreciate both the AD psychosis opportunity and the potential for pipeline repricing.

MapLight Therapeutics is viewed negatively because its lead muscarinic program looks like a late, contested entrant in schizophrenia, where Cobenfy is already approved and competing assets are advancing, leaving little room for a follower to win without clear superiority. ZEPHYR showed only modest efficacy on the 210/3 BID arm (PANSS Total −4.5 placebo-adjusted; ES 0.37, p=0.015), while the 330/6 QD arm missed, negative symptoms were weak, and adverse events remained material, including 74.7% TEAEs and 19.9% discontinuations. Even with better GI convenience and a supportive post-PIPE balance sheet, the need for another Phase 3 study and lower modeled peak sales of about $400mn in schizophrenia and $2bn in ADP support the view that upside is constrained.